ARMOR surveillance study update gives current insights on antibiotic resistance for clinical ocular isolatesThe most recent analyses of data from the ARMOR (Antibiotic Resistance Monitoring in Ocular micRoorganisms) Surveillance Program can guide clinicians choosing antibiotic therapy for initial empiric therapy and infection prophylaxis. The information also reinforces the importance of prudent antibiotic prescribing to limit the development of bacterial resistance to existing options, according to Penny Asbell, MD.
Reviewing anterior segment ARVO 2017 postersSo much basic science research is presented at this meeting, and most of it will be years before it makes its way to clinical trials. Let’s concentrate on research that might be of use to us in the exam room very soon.
Webinar: The ARMOR study five-year surveillance resultsWatch as Penny Asbell, MD, talks about antibiotic resistance in a webinar titled: The ARMOR Study Five-Year Surveillance Results.
Clinical advice from the latest ARMOR study updateIn the most recent update from the ARMOR study, Penny Asbell, MD, FACS, MBA, explained that clinicians must choose their antibiotics carefully.
Antibiotic resistance levels shift among ocular pathogens in 2014 ARMOR dataNew surveillance data on antibiotic resistance among ocular pathogens shows worrisome trends for some widely used drugs while resistance rates for some isolates were relatively stable.
ARMOR surveillance data update shows increased levels of resistanceThe latest surveillance data on antibiotic resistance trends show increased levels of resistance among certain isolates, warranting ongoing, prospective, multicenter surveillance studies.
B+L reports latest ARMOR study findings on bacterial resistance in ocular infectionsStudy researchers say that resistance rates have remained stable; however, more than 33% of certain isolates were resistant to three or more antibiotics.
ARMOR Study: 4-year data on antibiotic resistance of ocular pathogens